Deriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions!
|
|
|
- Zoe Parks
- 5 years ago
- Views:
Transcription
1 Deriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions! Casey L. Overby 1,2, Beth Devine 1, Peter Tarczy-Hornoch 1, Ira Kalet 1! 1 University of Washington, Seattle, WA! 2 Columbia University, New York, NY (current affiliation)! JAMIA Journal Club! September 6, 2012!
2 Pharmacogenomic evaluations of variability in drug exposure may facilitate personalized medicine! Cancer patient taking tamoxifen! The Doctor determines action based on individual characteristics! The Doctor modifies current therapy! The Doctor performs appropriate monitoring! Motivation
3 Pharmacogenomic evaluations of variability in drug exposure may facilitate personalized medicine! Cancer patient taking tamoxifen!? PGx profile data! The Doctor determines action based on individual characteristics! The Doctor modifies current therapy! The Doctor performs appropriate monitoring! Motivation
4 Pharmacogenomic evaluations of variability in drug exposure may facilitate personalized medicine! Cancer patient taking tamoxifen! PGx profile data! TAM!? CYP2C19! CYP2D6! CYP3A5! CYP3A5! CYP2C9! The Doctor determines action based on individual characteristics! The Doctor modifies current therapy! CYP2D6! N-Desmethyl TAM! CYP3A5! 4-OH TAM! The Doctor performs appropriate monitoring! Endoxifen! Motivation
5 Phenotype scores based on pharmacogenetic evaluations can be predictive of endoxifen levels! Several examples of assigning gene or enzyme activity scores to predict drug or metabolite response/level [Borges et al 2010, Gaedigk et al 2008, Zineh et al 2004]! Use a comparable scoring system! Use scoring system to predict drug/metabolite levels! How our scoring system and approach differs:! Incorporate contribution of several genes! Computational inference! Background
6 Computational inference based on pharmacological knowledge! DIKB Evidence Taxonomy! The Drug Interaction Knowledge-base [Boyce et al 2009]! Predicting metabolic inhibition and induction interactions! Components! Evidence base! Knowledge base! The DIKB Evidence taxonomy! Evidence Types Clinical trial types A pharmacokinetic clinical trial A genotyped pharmacokinetic clinical trial A phenotyped pharmacokinetic clinical trial Retrospective study types A retrospective population PK study In vitro experiment types A drug metabolism identification experiment A CYP450, recombinant, drug metabolism identification experiment with possibly NO probe enzyme inhibitor(s) A CYP450, human microsome, drug metabolism identification experiment using chemical inhibitors Observation based report An observation-based ADE report (e.g. FDA Adverse Event Reporting System) A published observation-based ADE report Non-traceable statement types A non-traceable, but possibly authoritative, statement A non-traceable drug-label statement Background
7 We use a computational approach to represent pharmacogenomic evaluations as a phenotype score! 1. Identify a clinical data source! 2. Identify pharmacogenomic evidence source(s)! 3. Derive assertions from sources to include in evidence base (EB) and knowledge base (KB)! 4. Define rules to reason over EB and KB assertions and calculate phenotype scores using various approaches! a. Initial literature base selection! b. Weighting enzymes! c. Scoring systems! 5. Evaluate various approaches! Background
8 Identify clinical data source! Consortium on Breast Cancer Pharmacogenomics (COBRA)! 30 breast cancer patients! 20 mg/day tamoxifen! genotype information: CYP3A5, -2D6, -2C9, and -2C19! phenotype information: endoxifen ng/ml and NDM ng/ml at 4 months! Tamoxifen PK pathway,! accessed via PharmGKB! Methods
9 Identify pharmacogenomics " evidence sources! Evidence Sources! PharmGKB (pharmgkb.org): drug metabolic knowledge (tamoxifen PK pathway)! SuperCYP (bioinformatics.charite.de/supercyp): gene variant - enzyme activity relationships! Primary literature review of gene variant - enzyme activity relationships (PharmGKB cited)! Review article: genotype - metabolizer activity relationships [Sheffield et al. Clin Bio Rev. 2009]! Methods
10 Scoring system! Raw from! Sheffield et al. Clin Bio Rev. 2009! Methods
11 Derived assertions from evidence and clinical data sources! Clinical data source assertions! Tamoxifen PK pathway assertions! Enzyme contribution assertions! allelic variant enzyme activity assertions! genotype metabolizer activity assertions! Patient clinical data source facts (patient (patient-mrn 001) (population white) (medications tamoxifen) (enz-tested cyp2c9 cyp2c19 cyp2d6 cyp3a5)) (patient-enz-genotype (patient-mrn 001) (enzyme cyp2c9) (allelic-variants cyp2c9_1 cyp2c9_1)) PK pathway facts (PharmGKB) (med-metabolite (name tamoxifen) (downstream-metabolite N-desmethyltamoxifen) (metabolizing-enzymes cyp3a4 cyp3a5)) (med-metabolite (name tamoxifen) (downstream-metabolite 4-OHtamoxifen) (metabolizing-enzymes cyp2d6 cyp2b6 cyp2c9 cyp2c19 cyp3a4 cyp3a5)) Allelic variant enzyme activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) Genotype metabolizer activity facts (Review article) (phenotype-activity-publication (pubmed-id ) (enzyme cyp2d6) (enz-allele1 decreased) (enz-allele2 nonfunctional) (phenotype-activity IM) (evidence-type review)) Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Methods
12 Derived assertions from evidence and clinical data sources! Clinical data source assertions! Tamoxifen PK pathway assertions! Enzyme contribution assertions! allelic variant enzyme activity assertions! genotype metabolizer activity assertions! Patient clinical data source facts (patient (patient-mrn 001) (population white) (medications tamoxifen) (enz-tested cyp2c9 cyp2c19 cyp2d6 cyp3a5)) (patient-enz-genotype (patient-mrn 001) (enzyme cyp2c9) (allelic-variants cyp2c9_1 cyp2c9_1)) PK pathway facts (PharmGKB) (med-metabolite (name tamoxifen) (downstream-metabolite N-desmethyltamoxifen) (metabolizing-enzymes cyp3a4 cyp3a5)) (med-metabolite (name tamoxifen) (downstream-metabolite 4-OHtamoxifen) (metabolizing-enzymes cyp2d6 cyp2b6 cyp2c9 cyp2c19 cyp3a4 cyp3a5)) Allelic variant enzyme activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) Genotype metabolizer activity facts (Review article) (phenotype-activity-publication (pubmed-id ) (enzyme cyp2d6) (enz-allele1 decreased) (enz-allele2 nonfunctional) (phenotype-activity IM) (evidence-type review)) Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Methods
13 Derived assertions from evidence and clinical data sources! Clinical data source assertions! Tamoxifen PK pathway assertions! Enzyme contribution assertions! allelic variant enzyme activity assertions! genotype metabolizer activity assertions! Patient clinical data source facts (patient (patient-mrn 001) (population white) (medications tamoxifen) (enz-tested cyp2c9 cyp2c19 cyp2d6 cyp3a5)) (patient-enz-genotype (patient-mrn 001) (enzyme cyp2c9) (allelic-variants cyp2c9_1 cyp2c9_1)) PK pathway facts (PharmGKB) (med-metabolite (name tamoxifen) (downstream-metabolite N-desmethyltamoxifen) (metabolizing-enzymes cyp3a4 cyp3a5)) (med-metabolite (name tamoxifen) (downstream-metabolite 4-OHtamoxifen) (metabolizing-enzymes cyp2d6 cyp2b6 cyp2c9 cyp2c19 cyp3a4 cyp3a5)) Allelic variant enzyme activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) CYP3A5! N-Desmethyl TAM! CYP3A4! TAM! CYP2C19! CYP3A5! CYP3A5! CYP2D6! CYP2B6! CYP2C9! 4-OH TAM! Genotype metabolizer activity facts (Review article) (phenotype-activity-publication (pubmed-id ) (enzyme cyp2d6) (enz-allele1 decreased) (enz-allele2 nonfunctional) (phenotype-activity IM) (evidence-type review)) Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Methods
14 Derived assertions from evidence and clinical data sources! Clinical data source assertions! Tamoxifen PK pathway assertions! Enzyme contribution assertions! allelic variant enzyme activity assertions! genotype metabolizer activity assertions! Patient clinical data source facts (patient (patient-mrn 001) (population white) (medications tamoxifen) (enz-tested cyp2c9 cyp2c19 cyp2d6 cyp3a5)) (patient-enz-genotype (patient-mrn 001) (enzyme cyp2c9) (allelic-variants cyp2c9_1 cyp2c9_1)) PK pathway facts (PharmGKB) (med-metabolite (name tamoxifen) (downstream-metabolite N-desmethyltamoxifen) (metabolizing-enzymes cyp3a4 cyp3a5)) (med-metabolite (name tamoxifen) (downstream-metabolite 4-OHtamoxifen) (metabolizing-enzymes cyp2d6 cyp2b6 cyp2c9 cyp2c19 cyp3a4 cyp3a5)) Allelic variant enzyme activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) CYP3A5! N-Desmethyl TAM! CYP3A4! TAM! CYP2C19! CYP3A5! CYP3A5! CYP2D6! CYP2B6! CYP2C9! 4-OH TAM! Genotype metabolizer activity facts (Review article) (phenotype-activity-publication (pubmed-id ) (enzyme cyp2d6) (enz-allele1 decreased) (enz-allele2 nonfunctional) (phenotype-activity IM) (evidence-type review)) Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Methods
15 Derived assertions from evidence and clinical data sources! Clinical data source assertions! Tamoxifen PK pathway assertions! Enzyme contribution assertions! allelic variant enzyme activity assertions! genotype metabolizer activity assertions! Patient clinical data source facts (patient (patient-mrn 001) (population white) (medications tamoxifen) (enz-tested cyp2c9 cyp2c19 cyp2d6 cyp3a5)) (patient-enz-genotype (patient-mrn 001) (enzyme cyp2c9) (allelic-variants cyp2c9_1 cyp2c9_1)) PK pathway facts (PharmGKB) (med-metabolite (name tamoxifen) (downstream-metabolite N-desmethyltamoxifen) (metabolizing-enzymes cyp3a4 cyp3a5)) (med-metabolite (name tamoxifen) (downstream-metabolite 4-OHtamoxifen) (metabolizing-enzymes cyp2d6 cyp2b6 cyp2c9 cyp2c19 cyp3a4 cyp3a5)) Allelic variant enzyme activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) Genotype metabolizer activity facts (Review article) (phenotype-activity-publication (pubmed-id ) (enzyme cyp2d6) (enz-allele1 decreased) (enz-allele2 nonfunctional) (phenotype-activity IM) (evidence-type review)) Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Methods
16 Derived assertions from evidence and clinical data sources! Clinical data source assertions! Tamoxifen PK pathway assertions! Enzyme contribution assertions! allelic variant enzyme activity assertions! genotype metabolizer activity assertions! Patient clinical data source facts (patient (patient-mrn 001) (population white) (medications tamoxifen) (enz-tested cyp2c9 cyp2c19 cyp2d6 cyp3a5)) (patient-enz-genotype (patient-mrn 001) (enzyme cyp2c9) (allelic-variants cyp2c9_1 cyp2c9_1)) PK pathway facts (PharmGKB) (med-metabolite (name tamoxifen) (downstream-metabolite N-desmethyltamoxifen) (metabolizing-enzymes cyp3a4 cyp3a5)) (med-metabolite (name tamoxifen) (downstream-metabolite 4-OHtamoxifen) (metabolizing-enzymes cyp2d6 cyp2b6 cyp2c9 cyp2c19 cyp3a4 cyp3a5)) Allelic variant enzyme activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) Genotype metabolizer activity facts (Review article) (phenotype-activity-publication (pubmed-id ) (enzyme cyp2d6) (enz-allele1 decreased) (enz-allele2 nonfunctional) (phenotype-activity IM) (evidence-type review)) Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Methods
17 Defined rules to calculate phenotype scores: evidence selection! Enzyme-oriented approach! 85 allelic variant enzyme activity facts (SuperCYP)! Drug-oriented approach! 7 facts (SuperCYP) + facts from 9 additional publications cited in PharmGKB! Enzyme allele activity facts (SuperCYP & PharmGKB) (enz-allele-activity-publication (pubmed-id ) (enz-allele cyp2d6_10a) (enz-activity decreased) (evidence-type in_vivo)) Methods
18 Defined rules to calculate phenotype scores: phenotype score calculation! Enzyme activity scoring: Un-weighted approach! Increased allele activity: 1.5! Wild-type allele activity: 1.0! Decreased allele Activity: 0.5! Non-functional allele activity: 0.0! Enzyme activity scoring: Weighted approach! Gene encodes major metabolizing enzyme: 1.0! Gene encodes minor metabolizing enzyme: 0.5! Enzyme contribution facts (PharmGKB) (enz-contribution (pubmed-id ) (enzyme cyp2d6) (major-minor major) (percent-contribution unknown)) Metabolizer activity scoring approach! Ultrarapid metaboliser (UM): 1.5! Extensive metaboliser (EM): 1.0! Intermediate metaboliser (IM): 0.5! Poor metaboliser (PM): 0.0! Methods
19 Defined rules to calculate phenotype scores: phenotype score calculation! Enzyme activity scoring: Un-weighted approach! Increased allele activity: 1.5! Wild-type allele activity: 1.0! Decreased allele Activity: 0.5! Non-functional allele activity: 0.0! Enzyme activity scoring: Weighted approach! Gene encodes major metabolizing enzyme: 1.0! Gene encodes minor metabolizing enzyme: 0.5! Metabolizer activity scoring approach! Ultrarapid metaboliser (UM): 1.5! Extensive metaboliser (EM): 1.0! Intermediate metaboliser (IM): 0.5! Poor metaboliser (PM): 0.0! Methods
20 Tamoxifen case study evaluation: " statistical methods! Are phenotype scores predictive of endoxifen/ndm plasma ratio?! Quantile linear regression! IV: phenotype score! DV: endoxifen/ndm plasma ratio! Are phenotype scores more predictive than simple methods for representing genotypes?! Quantile linear regression! IV: simple metric! DV: endoxifen/ndm plasma ratio! Simple metrics:! Single gene! Multiple genes! Additive model (wt/wt=0, vt/wt=1, vt/vt=2)! CYP3A5 Wt=*1, Vt=*3,*6 CYP2D6 Wt=*1, Vt=*4,*6 CYP2C9 Wt=*1, Vt=*2,*3 CYP2C19 Wt=*1, Vt=*2. Methods
21 Are phenotype scores predictive of " endoxifen/ndm plasma ratio?! Enzyme Activity Scoring! Metabolizer Activity Scoring! Results
22 Are phenotype scores predictive of " endoxifen/ndm plasma ratio?! Enzyme Activity Scoring! Metabolizer Activity Scoring! Results
23 Are phenotype scores more predictive than simple metrics?! One scoring approach performed better than simple metrics to represent genotypes for each gene! Results
24 Are phenotype scores more predictive than simple metrics?! One scoring approach performed better than a simple metric to represent multiple genes! Results
25 Challenges and limitations! Providing score in a useful way! Promotes appropriate use to make informed health decisions! Ensure the score is correct and current for the patient! Validity of score to predict response to therapy should be tested! CYP2D6 enzyme activity endoxifen concentrations clinical outcomes! Practical issues of implementing this model in an EHR should be investigated! Data and evidence source access, security, connection and coordination!
26 Contributions and future directions! Single score that characterizes combined activity of enzymes in a patientspecific way! Download and data access capabilities to support automated extraction of evidence! Other forms of clinical data and additional knowledge resources! Validation of methods for calculating phenotype scores with a separate dataset! More complicated polygenic models are needed to represent heterogenetiy in clinical outcomes!
27 Acknowledgements! Anonymous reviewers! Dr. Ken Thummel (UW Pharmaceutics)! Dr. Houda Hachad (UW Pharmaceutics)! Dr. Isabelle Ragueneau-Majlessi (UW Pharmaceutics)! Dr. David Flockhart & COBRA group for sharing data! UW Informatics research training grant (NIH NLM #T15 LM7442)! UW Genome training grant (NIH NHGRI #T32 HG000053)! Institute of Translational Health Sciences (NIH NCRR 1 UL1 RR )! Columbia Training in Biomedical Informatics (NIH NLM #T15 LM007079)! Mentored Clinical Scientist Training Grant (AHRQ 5K08 HS014739, PI: Devine)!
28 Questions?! Contact information:! Casey Lynnette Overby, PhD!
Core Data Set CYP2D6 Metabolism
Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole
Pharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
Ron van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience
Ron van Schaik Associate Professor Pharmacogenetics Eur Clin Chem / Advisor EMA - PGWG London, Oct 8-9, 2012 Pharmacogenetics Clinical implementation: a 7 year experience Pharmacogenetics Core Laboratory*
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;
CYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
Imipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
PHARMACOGENETICS OF BREAST CANCER
PHARMACOGENETICS OF BREAST CANCER MALGORZATA JAREMKO, PhD Mount Sinai School of Medicine, Department of Genetics and Genomic Sciences Outlines Breast cancer therapeutic situation Pharmacogenetics of antiestrogen
Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
INDIVIDUALIZED PATIENT THERAPY: IS IT MORE THAN A BUZZWORD?
INDIVIDUALIZED PATIENT THERAPY: IS IT MORE THAN A BUZZWORD? Kristin Wiisanen Weitzel, PharmD, FAPhA Clinical Associate Professor and Associate Chair, Pharmacotherapy and Translational Research, UF College
Pharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
Pharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
Genetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
Lang Li Department of Medical and Molecular Genetics Indiana Institute of Personalized Medicine Center for Computational Biology and Bioinformatics
Lang Li Department of Medical and Molecular Genetics Indiana Institute of Personalized Medicine Center for Computational Biology and Bioinformatics Indiana University School of Medicine A Tamoxifen Story:
Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
Psychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
Objectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6
Supplement to: Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update J. Kevin Hicks 1, Katrin Sangkuhl 2, Jesse J. Swen
Pharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy
DOI:10.22034/APJCP.2018.19.2.343 Polymorphisms in Drug Metabolizing Genes RESEARCH ARTICLE Editorial Process: Submission:01/03/2017 Acceptance:10/27/2017 Detection of Cytochrome P450 Polymorphisms in Breast
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
Two decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
LEIDEN, THE NETHERLANDS
Full-length CYP2D6 diplotyping for better drug dosage and response management Henk Buermans, PhD Leiden University Medical Center Human Genetics, LGTC LEIDEN, THE NETHERLANDS CYP2D6 Function Metabolism
Risperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
PHARMACOGENETICS. Marshalling the human genome to individualize drug therapy
PHARMACOGENETICS Marshalling the human genome to individualize drug therapy Prof. Ronen Loebstein Institute of Clinical Pharmacology & Toxicology Sheba Medical Center Some examples of drug response rates
Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Supplement to: Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants J. Kevin Hicks 1, Jesse J. Swen 2, Caroline F. Thorn 3, Katrin
CORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
Pharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
Pharmacogenomics and Pharmacokinetics ^
Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning
The effect of the CYP3A4*22, CYP3A5*3, and CYP3A combined. genotypes on tamoxifen metabolism. Introduction PHARMACOGENETICS
Eur J Clin Pharmacol (217) 73:1589 1598 DOI 1.17/s228-17-2323-2 PHARMACOGENETICS Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism A. B. Sanchez Spitman 1 & D. J. A. R.
Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions s
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/08/31/dmd.117.076455.dc1 1521-009X/45/11/1156 1165$25.00 https://doi.org/10.1124/dmd.117.076455 DRUG
Learning Objectives. Oncology I: Solid Tumors Last updated: August 2010
Learning Objectives Oncology I: Solid Tumors Last updated: August 2010 Upon completion of this program, participants will be able to: Identify specific drug therapies used in cardiology in which pharmacogenomic
Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing
Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing 2 Table of Contents Part One: Pharmacogenetics 101...Slides 4-16 Time Requirement: 20 minutes Part Two:
Genomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
Mental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing Brian Thomas Hocum, Pharm.D., CGP, Genelex Corporation, Seattle, WA (bhocum@genelex.com). John Raymond
Precision Medicine in Mental Health Care
Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans
MECHANISMS OF VARIABILITY IN CYP2D6 METABOLISM: THE CONTRIBUTIONS OF POLYMORPHISMS, COPY NUMBER VARIATIONS. AND microrna. Anuradha Ramamoorthy
MECHANISMS OF VARIABILITY IN CYP2D6 METABOLISM: THE CONTRIBUTIONS OF POLYMORPHISMS, COPY NUMBER VARIATIONS AND microrna Anuradha Ramamoorthy Submitted to the faculty of the University Graduate School in
CYP2D6 Genotype to Phenotype Standardization Project
CYP2D6 Genotype to Phenotype Standardization Project Project Objectives Determine a strategy for defining CYP2D6 phenotype based on genotype using a modified Delphi method. Standardize phenotype definitions
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
General Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has
San Filippo Neri Hospital- Rome
Pharmacogenetics in Breast Cancer Giampietro Gasparini, MD San Filippo Neri Hospital- Rome TUMOR PATIENT Few histotypes but more molecular diseases Pharmacogenomics DRUG Age and PS Comorbidities Compliance
William J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
Implementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
Pharmacogenomics. Research Article For reprint orders, please contact:
For reprint orders, please contact: reprints@futuremedicine.com Pharmacogenomics CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation
Article. Reference. Applications of CYP450 Testing in the Clinical Setting. SAMER, Caroline Flora, et al.
Article Applications of CYP450 Testing in the Clinical Setting SAMER, Caroline Flora, et al. Abstract Interindividual variability in drug response is a major clinical problem. Polymedication and genetic
FEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: 2.04.38 Cytochrome P450 Genotype-Guided Treatment Strategy Genotype-Guided Tamoxifen Treatment Description Tamoxifen is prescribed
Precision Medicine Under the Big Sky
Precision Medicine Under the Big Sky Erica L. Woodahl, Ph.D. Associate Professor Department of Biomedical and Pharmaceutical Sciences University of Montana Disclosure Statement Presenter has no financial
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
Big Data Course Week 7 Test2Learn TM 5/7/16
The site is http://api.test2learn.com Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need
Pharmacogenetics: Why some medications don t work - or make you feel worse - and what you can do about it.
Pharmacogenetics: Why some medications don t work - or make you feel worse - and what you can do about it. Dan Doherty Senior Personalized Prescribing Consultant Genelex / YouScript April 2015 EDS NYC
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects Dr. Francisco Abad Santos 16 June 2017 Atypical antipsychotics or second generation antipsychotics
Pharmacogenomics of Tamoxifen Therapy
Clinical Chemistry 55:10 1770 1782 (2009) Review Pharmacogenomics of Tamoxifen Therapy Hiltrud Brauch, 1,2* Thomas E. Mürdter, 1,2 Michel Eichelbaum, 1,2 and Matthias Schwab 1,2,3 BACKGROUND: Tamoxifen
Quetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
Application of Pharmacogenetics Supplementary Worksheet
Application of Pharmacogenetics Supplementary Worksheet Section 1 Health Care Problem Section 2 Drug Metabolism Section 3 Phase I & II metabolism Section 4 Inhibitors and Inducers Section 5 DNA & Drug
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
Cardiovascular pharmacogenomics: ready for prime time?
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
Genetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
Pharmacogenomics: Genetic variations in drug metabolism and utilization. Disclosure
Pharmacogenomics: Genetic variations in drug metabolism and utilization Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover,
Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur outline Definitions Genetic polymorphisms and drugs therapy a)warfarin b) Mercaptopurine c) Methotrexate d) Clopidogrel e) others
William J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2011 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
CYP2D6 and the oestrogen receptor
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/cyp2d6-and-the-oestrogenreceptor/ CYP2D6 and the oestrogen receptor The medicinal adjuvant therapy of breast cancer is
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
Pharmacogenetics and Pharmacokinetics
Chapter 2 Pharmacogenetics and Pharmacokinetics Mauro Saivezzo/ShutterStock, Inc. L earning O bjectives Upon completion of this chapter, the student will be able to: 1. Recognize the influence of genetic
Impact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline - a study based on therapeutic drug monitoring data
Impact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline - a study based on therapeutic drug monitoring data Ida Rudberg 2009 Department of Psychopharmacology Diakonhjemmet
Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytochrome p450 Genotyping Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See Also: Cytochrome p450 Genotyping Genetic Testing for Helicobacter
Implémentation clinique de la pharmacogénétique
Implémentation clinique de la pharmacogénétique Vincent HAUFROID Cliniques Universitaires St Luc Université catholique de Louvain Louvain centre for Toxicology and Applied Pharmacology (LTAP) Pharmacogenetics:
Centre for Research Ethics & Bioethics
Managing incidental findings and research results in genomics Mats Hansson Assigning rights to donors, Wolf et al. Gen Med 2012 Adapted from biobank context: 1. Clarify the criteria for evaluating findings
Pharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
HUMAN BIOTRANSFORMATION. ANDREW PARKINSON, BRIAN W. OGILVIE, BRANDY L. PARIS, TIFFINI N. HENSLEY, and GREG J. LOEWEN XenoTech LLC, Lenexa, KS
CHAPTER 1 HUMAN BIOTRANSFORMATION ANDREW PARKINSON, BRIAN W. OGILVIE, BRANDY L. PARIS, TIFFINI N. HENSLEY, and GREG J. LOEWEN XenoTech LLC, Lenexa, KS 1.1 INTRODUCTION Biotransformation is the enzyme -
Variation in drug responses & Drug-Drug Interactions
Variation in drug responses & Drug-Drug Interactions 1 Properties of an Ideal Drug Effective Safety Selective Reversible Action Predictable Freedom from drug interactions Low cost Chemically stable Sources
FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)
FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance) Kellie S. Reynolds, Pharm.D. Deputy Director, Division of Clinical Pharmacology IV Office of Clinical Pharmacology (OCP) Office of
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
nature publishing group Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott 1, K Sangkuhl 2, EE Gardner 3, CM Stein
Personalized Medicine & Treatments
Personalized Medicine & Treatments NASCHIP September 14, 2007 Teresa DeLuca, MD, MBA Vice President Department of Personalized Medicine Medco is a registered trademark of Medco Health Solutions, Inc. Pipeline
6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer
6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer Saad J. Sirop, MD James N. Ingle, MD Matthew P. Goetz, MD Introduction
WHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
INDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
Releasing SNP Data and GWAS Results with Guaranteed Privacy Protection
integrating Data for Analysis, Anonymization, and SHaring Releasing SNP Data and GWAS Results with Guaranteed Privacy Protection Xiaoqian Jiang, PhD and Shuang Wang, PhD Overview Introduction idash healthcare
Falk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
Perceived challenges in genomic-based drug development. Garret A. FitzGerald University of Pennsylvania
Perceived challenges in genomic-based drug development Garret A. FitzGerald University of Pennsylvania Genomics Based Personalization of Medicine A Case in Point in Cancer Aside from emerging resistance.
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
British Journal of Clinical Pharmacology DOI:10.1111/bcp.12665 In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles Daniel L. Hertz, 1 Anna C. Snavely, 2 Howard L. McLeod, 3 Christine
Cytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
The role of pharmacogenetics in drug-induced toxicity
The role of pharmacogenetics in drug-induced toxicity Is there anybody today who does not use any medication? The total turnover of pharmaceutical care in the Netherlands in 2014 was 4.3 billion euros.
The importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development Jean Lopategui, MD Director, Molecular Pathology Jean.lopategui@cshs.org Warfarin Pharmacogenomics Part I Background Information
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
Drug Gene Interactions: Inherent Variability In Drug Maintenance Dose Requirements
Drug Gene Interactions: Inherent Variability In Drug Maintenance Dose Requirements Paul Wester velt; Kihoon Cho; David R. Bright, PharmD; and David F. Kisor, PharmD Key words: drug gene interaction, pharmacogenetics,
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
Comprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
Pharmacogenomics: Assessment of Therapeutic Risk vs Benefit
Pharmacogenomics: Assessment of Therapeutic Risk vs Benefit Lawrence J. Lesko Clinical Professor Center for Pharmacometrics and Systems Pharmacology University of Florida at Lake Nona November 15, 2016
Variability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
Original Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return